Morroniside alleviates lipopolysaccharide-induced inflammatory and oxidative stress in inflammatory bowel disease by inhibiting NLRP3 and NF-l=kB signaling pathways
Allergol. immunopatol
; 50(6): 93-99, 01 nov. 2022. graf, ilus
Artigo
em Inglês
| IBECS
| ID: ibc-211510
Biblioteca responsável:
ES1.1
Localização: ES15.1 - BNCS
ABSTRACT
Objective To investigate the effects of morroniside on inflammatory and oxidative stress in lipopolysaccharide (LPS)-induced inflammatory bowel disease (IBD) cell model. Methods NCM460 cells were treated with 2-, 5-, or 10-μg/mL LPS for 24 h to develop an IBD cell model. MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide) colorimetric assay was performed to uncover the role of morroniside on the viability of LPS-treated NCM460 cells. Flow cytometry and immunoblot assays were performed to confirm the effects of morroniside on the apoptosis of LPS-treated NCM460 cells. Quantitative polymerase chain reaction and enzyme-linked-immunosorbent serologic assays were performed to confirm the effects of morroniside on inflammatory and oxidative stress by measuring the levels of tumor necrosis factor-α, interleukin-1β, IL-6, superoxide dismutase, malondialdehyde, total antioxidant capacity, and myeloperoxidase. In addition, immunoblot and immunofluorescence assays were performed to detect the effects of morroniside on NLRP3 and NF-κB pathways. Results Monosine attenuated LPS-induced injury of NCM460 cells. Monosine reduced LPS-induced inflammation in NCM460 cells. In addition, morroniside reduced LPS-induced oxidative stress in NCM460 cells. Mechanically, morroniside suppressed NLRP3 and NF-κB pathways, and alleviated LPS-induced inflammatory and oxidative stress in IBD. Conclusion Morroniside could serve as a promising drug for treating IBD (AU)
Texto completo:
Disponível
Coleções:
Bases de dados nacionais
/
Espanha
Base de dados:
IBECS
Assunto principal:
Doenças Inflamatórias Intestinais
/
Transdução de Sinais
/
Lipopolissacarídeos
/
Estresse Oxidativo
Limite:
Humanos
Idioma:
Inglês
Revista:
Allergol. immunopatol
Ano de publicação:
2022
Tipo de documento:
Artigo
Instituição/País de afiliação:
Shenzhen Second Peoples Hospital/China
/
Southern University of Science and Technology)/China